(EL) Estee Lauder Companies - Ratings and Ratios
SkinCare, Makeup, Fragrance, HairCare
EL EPS (Earnings per Share)
EL Revenue
Description: EL Estee Lauder Companies
Estee Lauder Companies Inc is a global cosmetics conglomerate with a diverse portfolio of brands across skin care, makeup, fragrance, and hair care. The companys product offerings cater to various consumer needs, with a presence in multiple distribution channels, including department stores, specialty retailers, online platforms, and freestanding stores.
From a brand perspective, Estee Lauder Companies Inc has a strong stable of premium and mass-market brands, including Estée Lauder, Clinique, M·A·C, La Mer, and Aveda, among others. This diversification allows the company to tap into different consumer segments and geographies, potentially driving revenue growth and profitability. Key Performance Indicators (KPIs) to watch include revenue growth, gross margin expansion, and brand momentum, particularly in emerging markets and e-commerce channels.
In terms of operational efficiency, metrics such as inventory turnover, accounts receivable days, and supply chain optimization will be crucial in evaluating the companys ability to manage its working capital and respond to changing consumer demands. Additionally, the companys commitment to innovation, sustainability, and digital transformation will likely play a significant role in shaping its long-term competitiveness and growth prospects.
From a financial perspective, key metrics to monitor include Return on Equity (ROE), although the current negative ROE of -18.42% warrants close attention. Other important KPIs include operating margin, free cash flow generation, and debt-to-equity ratio, which can provide insights into the companys ability to service its debt, invest in growth initiatives, and reward shareholders. A detailed analysis of these metrics will help investors better understand the companys financial health and prospects for long-term value creation.
EL Stock Overview
| Market Cap in USD | 31,557m |
| Sub-Industry | Personal Care Products |
| IPO / Inception | 1995-11-16 |
EL Stock Ratings
| Growth Rating | -38.1% |
| Fundamental | 28.2% |
| Dividend Rating | 46.2% |
| Return 12m vs S&P 500 | -11.5% |
| Analyst Rating | 3.11 of 5 |
EL Dividends
| Dividend Yield 12m | 1.27% |
| Yield on Cost 5y | 0.51% |
| Annual Growth 5y | 9.35% |
| Payout Consistency | 97.9% |
| Payout Ratio | 114.0% |
EL Growth Ratios
| Growth Correlation 3m | 83% |
| Growth Correlation 12m | -5.9% |
| Growth Correlation 5y | -86.3% |
| CAGR 5y | -15.12% |
| CAGR/Max DD 5y | -0.18 |
| Sharpe Ratio 12m | -0.38 |
| Alpha | -19.23 |
| Beta | 1.293 |
| Volatility | 41.72% |
| Current Volume | 2357.9k |
| Average Volume 20d | 3639.7k |
| Stop Loss | 87.4 (-4.7%) |
| Signal | 0.60 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-1.13b TTM) > 0 and > 6% of Revenue (6% = 859.6m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -3.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.41% (prev 14.22%; Δ -2.82pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 1.27b > Net Income -1.13b (YES >=105%, WARN >=100%) |
| Net Debt (6.52b) to EBITDA (741.0m) ratio: 8.80 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (360.7m) change vs 12m ago 0.36% (target <= -2.0% for YES) |
| Gross Margin 73.97% (prev 71.66%; Δ 2.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 68.93% (prev 72.00%; Δ -3.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.32 (EBITDA TTM 741.0m / Interest Expense TTM 404.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.19
| (A) 0.08 = (Total Current Assets 7.07b - Total Current Liabilities 5.43b) / Total Assets 19.89b |
| (B) 0.59 = Retained Earnings (Balance) 11.67b / Total Assets 19.89b |
| (C) 0.01 = EBIT TTM 131.0m / Avg Total Assets 20.78b |
| (D) 0.66 = Book Value of Equity 10.55b / Total Liabilities 16.03b |
| Total Rating: 3.19 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.23
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 1.69% = 0.85 |
| 3. FCF Margin 4.68% = 1.17 |
| 4. Debt/Equity 2.85 = -0.54 |
| 5. Debt/Ebitda 14.85 = -2.50 |
| 6. ROIC - WACC -7.38% = -9.23 |
| 7. RoE -25.95% = -2.50 |
| 8. Rev. Trend -48.42% = -2.42 |
| 9. Rev. CAGR -5.02% = -0.84 |
| 10. EPS Trend -70.26% = -1.76 |
| 11. EPS CAGR -51.23% = -2.50 |
What is the price of EL shares?
Over the past week, the price has changed by +0.55%, over one month by +0.36%, over three months by +34.27% and over the past year by +3.53%.
Is Estee Lauder Companies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EL is around 83.29 USD . This means that EL is currently overvalued and has a potential downside of -9.2%.
Is EL a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 23
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the EL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 89.4 | -2.6% |
| Analysts Target Price | 69.1 | -24.7% |
| ValueRay Target Price | 92.7 | 1% |
Last update: 2025-08-23 02:49
EL Fundamental Data Overview
CCE Cash And Equivalents = 2.92b USD (Cash And Short Term Investments, last quarter)
P/E Forward = 40.8163
P/S = 2.2028
P/B = 7.1677
P/EG = 1.7754
Beta = 1.176
Revenue TTM = 14.33b USD
EBIT TTM = 131.0m USD
EBITDA TTM = 741.0m USD
Long Term Debt = 10.59b USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 409.0m USD (from shortTermDebt, last quarter)
Debt = 11.00b USD (Calculated: Short Term 409.0m + Long Term 10.59b)
Net Debt = 6.52b USD (from netDebt column, last quarter)
Enterprise Value = 39.64b USD (31.56b + Debt 11.00b - CCE 2.92b)
Interest Coverage Ratio = 0.32 (Ebit TTM 131.0m / Interest Expense TTM 404.0m)
FCF Yield = 1.69% (FCF TTM 670.0m / Enterprise Value 39.64b)
FCF Margin = 4.68% (FCF TTM 670.0m / Revenue TTM 14.33b)
Net Margin = -7.91% (Net Income TTM -1.13b / Revenue TTM 14.33b)
Gross Margin = 73.97% ((Revenue TTM 14.33b - Cost of Revenue TTM 3.73b) / Revenue TTM)
Tobins Q-Ratio = 3.76 (Enterprise Value 39.64b / Book Value Of Equity 10.55b)
Interest Expense / Debt = 1.23% (Interest Expense 135.0m / Debt 11.00b)
Taxrate = 21.0% (US default)
NOPAT = 103.5m (EBIT 131.0m * (1 - 21.00%))
Current Ratio = 1.30 (Total Current Assets 7.07b / Total Current Liabilities 5.43b)
Debt / Equity = 2.85 (Debt 11.00b / last Quarter total Stockholder Equity 3.87b)
Debt / EBITDA = 14.85 (Net Debt 6.52b / EBITDA 741.0m)
Debt / FCF = 16.42 (Debt 11.00b / FCF TTM 670.0m)
Total Stockholder Equity = 4.37b (last 4 quarters mean)
RoA = -5.70% (Net Income -1.13b, Total Assets 19.89b )
RoE = -25.95% (Net Income TTM -1.13b / Total Stockholder Equity 4.37b)
RoCE = 0.88% (Ebit 131.0m / (Equity 4.37b + L.T.Debt 10.59b))
RoIC = 0.86% (NOPAT 103.5m / Invested Capital 12.00b)
WACC = 8.24% (E(31.56b)/V(42.56b) * Re(10.78%)) + (D(11.00b)/V(42.56b) * Rd(1.23%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -35.90 | Cagr: -0.36%
Discount Rate = 10.78% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 59.21% ; FCFE base≈978.4m ; Y1≈642.4m ; Y5≈293.8m
Fair Price DCF = 16.81 (DCF Value 3.94b / Shares Outstanding 234.2m; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -48.42 | Revenue CAGR: -5.02%
Rev Growth-of-Growth: -3.38
EPS Correlation: -70.26 | EPS CAGR: -51.23%
EPS Growth-of-Growth: -14.30
Additional Sources for EL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle